LOGIN  |  REGISTER
C4 Therapeutics
Cue Biopharma

Humana to Present at 2025 Wolfe Research Healthcare Conference

November 06, 2025 | Last Trade: US$252.04 0.93 0.37

LOUISVILLE, Ky. / Nov 06, 2025 / Business Wire / Humana Inc. (NYSE: HUM) announced today that Celeste Mellet, Chief Financial Officer, will make a presentation to investors at the Wolfe Research Healthcare Conference on Wednesday, November 19, 2025, at 8:40 a.m. Eastern time.

A live audio webcast of the presentation will be available via Humana’s Investor Relations page at https://humana.gcs-web.com/. The company suggests webcast participants sign on approximately 15 minutes in advance of the presentation to allow time to run a system test and download any free software needed for access purposes.

About Humana

Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.

C4 Therapeutics

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page